Table 1.
Clinical application of bispecific antibody in advanced tumors.
| Researchers | Drug name | Tumor type | Clinical results |
|---|---|---|---|
| gp100 × CD3 | |||
| Nathan et al. (27) | Tebentafusp | Metastatic uveal melanoma | 1-year OS:76%; Median OS: 21.7months (first-line treatment) |
| Carvajal et al. (28) | Tebentafusp | Metastatic uveal melanoma | 1-year OS: 62%; Median OS:16.8 months (Received previous treatment) |
| CD73 × TGF-β | |||
| Tolcher et al. (29) | Dalutrafusp alfa | Advanced solid tumors | ORR:4.8%; DCR:38.1% |
| CTLA-4 × PD-1 | |||
| Zhao et al. (30) | QL1706 | Advanced solid tumors | ORR: 12.5%~33% |
| Ma et al. (31) | KN046 | Advanced solid tumors | Median OS:16.6 months |
| Pang et al. (32) | Cadonilimab | Advanced solid tumors | ORR:33% |
gp100, glycoprotein 100; CD, cluster of differentiation; TGF-β, transforming growth factor-β; CTLA-4, cytotoxic T lymphocyte-associated antigen-4; PD-1, programmed death-1; OS, overall survival; ORR, objective response rate; DCR, disease control rate.